Jones Trading Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $42
Portfolio Pulse from Benzinga Newsdesk
Jones Trading has initiated coverage on Rapport Therapeutics with a Buy rating and set a price target of $42.
October 18, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jones Trading has initiated coverage on Rapport Therapeutics with a Buy rating and a price target of $42, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $42 by Jones Trading suggests a positive sentiment towards Rapport Therapeutics. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100